Copellor (Ixekizumab) India — What Hospitals and Dermatologists Need to Know
1. What Is Copellor (Ixekizumab)? Copellor® is the brand name for Ixekizumab, a humanised anti-interleukin-17A (anti-IL-17A) IgG4 monoclonal antibody manufactured by Eli Lilly and Company India Pvt Ltd and approved by the Drugs Controller General of India (DCGI). It is available as an 80mg/mL subcutaneous injection in a pre-filled syringe or auto-injector. Ixekizumab works by […]
